What are the differences between betahistine (Betaserc) and cinnarizine (Stemetil) in the treatment of vertigo?

Betahistine (Betaserc) vs Prochlorperazine (Stemetil) in Vertigo

For acute peripheral vertigo, use prochlorperazine (Stemetil) for immediate symptom relief, but limit to short-term use only; betahistine (Betaserc) has questionable efficacy even for maintenance therapy and should not be first-line for any vertigo indication based on the highest quality evidence.

Critical Evidence Gap

The provided evidence does not contain information about prochlorperazine (Stemetil) - the studies compare betahistine with cinnarizine, not Stemetil. However, I can address betahistine's role based on the strongest available guideline evidence.

Betahistine (Betaserc): Limited Efficacy

Key Evidence from Highest Quality Study

The 2020 American Academy of Otolaryngology Clinical Practice Guideline 1 highlights the BEMED trial as the most rigorous evidence:

• No benefit over placebo: The well-designed BEMED trial found no significant differences in mean vertigo attack rates between placebo, low-dose betahistine (48 mg/d), and high-dose betahistine (144 mg/d) over 9 months 1
• Guideline conclusion: "Currently, this CPG committee is unable to make a definitive statement on use of betahistine to control MD symptoms" 1
• Policy level: Only an "option" (not recommendation) for maintenance therapy 2

When Betahistine Might Be Considered

Despite limited evidence, betahistine may be offered as maintenance therapy for Ménière's disease 1, 2:

• Dosing: 48-144 mg daily divided doses
• Cautions: Avoid in pheochromocytoma; use cautiously with asthma or peptic ulcer disease 1
• Side effects: Generally mild (headache, nausea, GI symptoms) 1

Cinnarizine Comparisons (Not Stemetil, but Relevant)

Since the evidence compares betahistine to cinnarizine (not Stemetil):

Combination Therapy Superior

• Cinnarizine/dimenhydrinate fixed combination consistently outperforms betahistine monotherapy 3, 4, 5
• A 2019 RCT showed the combination was superior (not just non-inferior) to betahistine 16 mg for peripheral vestibular vertigo 5
• The combination reduced mean vertigo scores more effectively at both 1 week and 4 weeks 6, 5

Monotherapy Comparison

• Studies show mixed results when comparing betahistine vs cinnarizine alone 7, 8, 9
• One study favored betahistine for Ménière's disease 7
• Another favored betahistine for migraine-associated vertigo 8
• A 1986 crossover study found equal efficacy but betahistine had fewer attacks and less drowsiness 9

Clinical Algorithm for Vertigo Treatment

For Acute Vertigo:

1. Use vestibular suppressants (like prochlorperazine) for immediate symptom control only - limit to 2-3 days maximum
2. Do NOT use betahistine for acute attacks 2
3. Do NOT use vestibular rehabilitation during acute attacks 2

For Maintenance/Prevention (Ménière's Disease):

1. First-line: Dietary sodium restriction (1500-2300 mg/day) 1
2. Second-line: Consider diuretics or betahistine as options (not strong recommendations) 2
3. If inadequate response: Progress to intratympanic steroids 2
4. Refractory cases: Consider surgical options

For Chronic Imbalance:

• Vestibular rehabilitation is appropriate for interictal instability 2

Critical Pitfalls

• Avoid prolonged vestibular suppressants: They impair central compensation and prolong recovery
• Betahistine is not proven effective: The best evidence (BEMED trial) shows no benefit over placebo 1
• Don't confuse cinnarizine with prochlorperazine: These are different drug classes with different mechanisms
• Reassess regularly: If using betahistine, monitor for symptom improvement and consider discontinuation if no benefit after 2-3 months 1